SMA-MAP: A Plasma Protein Panel for Spinal Muscular Atrophy

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Kobayashi, Dione T ^a   Shi, Jing ^b   Stephen, Laurie ^c   Ballard, Karri L ^c   Dewey, Ruth ^c   Mapes, James ^c   Chung, Brett ^a   McCarthy, Kathleen ^a   Swoboda, Kathryn J ^d   Crawford, Thomas O ^e   Li, Rebecca ^f   Plasterer, Thomas ^g   Joyce, Cynthia ^a   Acsadi, G ^a   Campbell, C ^a   Coates, A ^a   Connolly, A M ^a   Iannaccone, S T ^a   Khongkhatithum, C ^a   Kissel, J T ^a   Kolb, S J ^a   Kunz, N L ^a   Makris, C ^a   Mathews, K D ^a   Matthews, D ^a   Schroth, M K ^a   Vajsar, J ^a   Wang, C H ^a   Wong, B L ^a   Sahin, M ^a   Antiel, L ^a   Florence, J ^a   Gee, R ^a   Glanzman, A M ^a,h   Hartman, J ^a   King, W ^a   Krosschell, K ^a   Laubenthal, K ^a   McGuire, M ^a   Montes, J ^a,h   Nelson, L ^a   Owen, J ^a   Patterson, K ^a   Quigley, J ^a,h   Roman, C ^a   Riley, S ^a,h   Scholtes, C ^a   Sedlacek, P ^a   Siener, C ^a   Strumpf, S ^a   Wood, J ^a   Ameli, J ^a   Andersen, M ^a   Bell, M ^a   Benton, M ^a,h   Binner, H ^a   Butler, H ^a,h   Chelnick, S ^a   Clayton, J ^a   Faut, S ^a   Forrest, S ^a   MacMillan, L ^a   Martensen, M ^a   Montgomery, M ^a   Morehart, P ^a   Pharo, L ^a   Reeves, G ^a   Stephan, C ^a   Taranik, R ^a   Tsai, O ^a   Wedell, V ^a   Wulf, C ^a   Chung, Wendy K ^h   Kaufmann, Petra ^h   Darras, Basil T ^h   Finkel, Richard S ^h   Sproule, Douglas M ^h   Martens, William B ^h   McDermott, Michael P ^h   De Vivo, Darryl C ^h   Constantinescu, A ^h   Foley, A R ^h   Gooch, CL ^h   Kang, P B ^h   O'Hagen, J ^h   Oskoui, M ^h   Punyanitya, M ^h   Tawil, R ^h   Yang, M ^h   Dunaway, S ^h   Flinckinger, J ^h   Ryan, P A ^h   Battista, V ^h   Koo, B ^h   Marra, J ^h   Montgomery, M J ^h   Deng, L ^h   Guo, J ^h   Lanzano, P ^h   Walker, Michael G ^b   Chen, Karen S ^a   more..

^a Spinal Muscular Atrophy Foundation   (United States)

^b Walker Bioscience   (United States)

^c Myriad RBM   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS CHILDREN S CENTER   (United States)

^f NEW ENGLAND RESEARCH INSTITUTES   (United States)

^g BG Medicine   (United States)

^h The Pediatric Neuromuscular Clinical Research Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICROTUBULE ASSOCIATED PROTEIN; SURVIVAL MOTOR NEURON PROTEIN;

ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOASSAY; INFANT; MAJOR CLINICAL STUDY; MOTOR PERFORMANCE; OUTCOME ASSESSMENT; PREDICTION; PRESCHOOL CHILD; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUALITY OF LIFE; SCHOOL CHILD; SPINAL MUSCULAR ATROPHY;

EID: 84875656670     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060113     Document Type: Article

References (77)

1. Van Meerbeke JP, Sumner CJ, (2011) Progress and promise: the current status of spinal muscular atrophy therapeutics. Discov Med 12: 291-305.
2. Kissel JT, Scott CB, Reyna SP, Crawford TO, Simard LR, et al. (2011) SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One 6: e21296.
3. Mercuri E, Bertini E, Messina S, Pelliccioni M, D'Amico A, et al. (2004) Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 14: 130-135.
4. Pane M, Staccioli S, Messina S, D'Amico A, Pelliccioni M, et al. (2008) Daily salbutamol in young patients with SMA type II. Neuromuscul Disord 18: 536-540.
5. Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, et al. (2009) Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One 4: e5268.
6. Wadman RI, Bosboom WM, van der Pol WL, van den Berg LH, Wokke JH, et al. (2012) Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev 4: CD006282.
7. Wadman RI, Bosboom WM, van der Pol WL, van den Berg LH, Wokke JH, et al. (2012) Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev. 4: CD006281.
8. Miller RG, Moore DH, Dronsky V, Bradley W, Barohn R, et al. (2001) A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 191: 127-131.
9. Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, et al. (2010) SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One 5: e12140.
10. Main M, Kairon H, Mercuri E, Muntoni F, (2003) The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol 7: 155-159.
11. Bromberg MB, Swoboda KJ, (2002) Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve 25: 445-447.
12. Cook JD, Iannaccone ST, Russman BS, Samaha F, Buncher RR, et al. (1990) A methodology to measure the strength of SMA patients. Dallas-Cincinnati-Newington Spinal Muscular Atrophy (DCN-SMA) Study Group. Muscle Nerve 13Suppl: S7-10.
13. Iannaccone ST, Hynan LS, Morton A, Buchanan R, Limbers CA, et al. (2009) The PedsQL in pediatric patients with Spinal Muscular Atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Neuromuscular Module. Neuromuscul Disord 19: 805-812.
14. Iannaccone ST, Russman BS, Browne RH, Buncher CR, White M, et al. (2000) Prospective analysis of strength in spinal muscular atrophy. DCN/Spinal Muscular Atrophy Group. J Child Neurol 15: 97-101.
15. Kaufmann P, McDermott MP, Darras BT, Finkel R, Kang P, et al. (2011) Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol 68: 779-786.
16. Krosschell KJ, Maczulski JA, Crawford TO, Scott C, Swoboda KJ, (2006) A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord 16: 417-426.
17. Lewelt A, Krosschell KJ, Scott C, Sakonju A, Kissel JT, et al. (2010) Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve 42: 703-708.
18. Nelson L, Owens H, Hynan LS, Iannaccone ST, Am SG, (2006) The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord 16: 374-380.
19. O'Hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, et al. (2007) An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord 17: 693-697.
20. Samaha FJ, Buncher CR, Russman BS, White ML, Iannaccone ST, et al. (1994) Pulmonary function in spinal muscular atrophy. J Child Neurol 9: 326-329.
21. Tiziano FD, Neri G, Brahe C, (2010) Biomarkers in rare disorders: the experience with spinal muscular atrophy. Int J Mol Sci 12: 24-38.
22. Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, et al. (2012) Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology.
23. Rutkove SB, Shefner JM, Gregas M, Butler H, Caracciolo J, et al. (2010) Characterizing spinal muscular atrophy with electrical impedance myography. Muscle Nerve 42: 915-921.
24. Sproule DM, Punyanitya M, Shen W, Dashnaw S, Martens B, et al. (2011) Muscle volume estimation by magnetic resonance imaging in spinal muscular atrophy. J Child Neurol 26: 309-317.
25. Crawford TO, Paushkin SV, Kobayashi DT, Forrest SJ, Joyce CL, et al. (2012) Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One 7: e33572.
26. Finkel RS, Crawford TO, Swoboda KJ, Kaufmann P, Juhasz P, et al. (2012) Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study. PLoS One 7: e35462.
27. Long JS (1997) Limited outcome: The Tobit model. Regression models for categorical and limited dependent variables: SAGE Publications. 187-216.
28. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, et al. (2011) Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478: 123-126.
29. Bosch-Marce M, Wee CD, Martinez TL, Lipkes CE, Choe DW, et al. (2011) Increased IGF-1 in muscle modulates the phenotype of severe SMA mice. Hum Mol Genet 20: 1844-1853.
30. Murdocca M, Malgieri A, Luchetti A, Saieva L, Dobrowolny G, et al. (2012) IPLEX administration improves motor neuron survival and ameliorates motor functions in a severe mouse model of SMA. Mol Med.
31. Shababi M, Glascock J, Lorson CL, (2011) Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy. Hum Gene Ther 22: 135-144.
32. Millino C, Fanin M, Vettori A, Laveder P, Mostacciuolo ML, et al. (2009) Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy. BMC Med 7: 14.
33. Kobayashi DT, Decker D, Zaworski P, Klott K, McGonigal J, et al. (2012) Evaluation of peripheral blood mononuclear cell processing and analysis for survival motor neuron protein. PLoS One 7: e50763.
34. Tiziano FD, Lomastro R, Di Pietro L, Barbara Pasanisi M, Fiori S, et al. (2012) Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study. Eur J Hum Genet.
35. Bowerman M, Swoboda KJ, Michalski JP, Wang GS, Reeks C, et al. (2012) Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann Neurol 72: 256-268.
36. Crawford TO, Sladky JT, Hurko O, Besner-Johnston A, Kelley RI, (1999) Abnormal fatty acid metabolism in childhood spinal muscular atrophy. Ann Neurol 45: 337-343.
37. Ling KK, Gibbs RM, Feng Z, Ko CP, (2012) Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy. Hum Mol Genet 21: 185-195.
38. Mutsaers CA, Wishart TM, Lamont DJ, Riessland M, Schreml J, et al. (2011) Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. Hum Mol Genet 20: 4334-4344.
39. Franco SJ, Muller U, (2011) Extracellular matrix functions during neuronal migration and lamination in the mammalian central nervous system. Dev Neurobiol 71: 889-900.
40. Liu A, Niswander LA, (2005) Bone morphogenetic protein signalling and vertebrate nervous system development. Nat Rev Neurosci 6: 945-954.
41. Fernandez-Puente P, Mateos J, Fernandez-Costa C, Oreiro N, Fernandez-Lopez C, et al. (2011) Identification of a panel of novel serum osteoarthritis biomarkers. J Proteome Res 10: 5095-5101.
42. Burch GH, Gong Y, Liu W, Dettman RW, Curry CJ, et al. (1997) Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. Nat Genet 17: 104-108.
43. Martin I, Jakob M, Schafer D, Dick W, Spagnoli G, et al. (2001) Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints. Osteoarthritis Cartilage 9: 112-118.
44. Xu G, Sun W, He D, Wang L, Zheng W, et al. (2005) Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 32: 410-416.
45. Shanmugarajan S, Tsuruga E, Swoboda KJ, Maria BL, Ries WL, et al. (2009) Bone loss in survival motor neuron (Smn(-/-) SMN2) genetic mouse model of spinal muscular atrophy. J Pathol 219: 52-60.
46. Shanmugarajan S, Swoboda KJ, Iannaccone ST, Ries WL, Maria BL, et al. (2007) Congenital bone fractures in spinal muscular atrophy: functional role for SMN protein in bone remodeling. J Child Neurol 22: 967-973.
47. Tyrberg B, Miles P, Azizian KT, Denzel MS, Nieves ML, et al. (2011) T-cadherin (Cdh13) in association with pancreatic beta-cell granules contributes to second phase insulin secretion. Islets 3: 327-337.
48. Neumiller JJ, Wood L, Campbell RK, (2010) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 30: 463-484.
49. Cohen E, Dillin A, (2008) The insulin paradox: aging, proteotoxicity and neurodegeneration. Nat Rev Neurosci 9: 759-767.
50. Sproule DM, Montes J, Dunaway S, Montgomery M, Battista V, et al. (2010) Adiposity is increased among high-functioning, non-ambulatory patients with spinal muscular atrophy. Neuromuscul Disord 20: 448-452.
51. Sproule DM, Hasnain R, Koenigsberger D, Montgomery M, De Vivo DC, et al. (2012) Age at disease onset predicts likelihood and rapidity of growth failure among infants and young children with spinal muscular atrophy types 1 and 2. J Child Neurol 27: 845-851.
52. Paracchini V, Pedotti P, Taioli E, (2005) Genetics of leptin and obesity: a HuGE review. Am J Epidemiol 162: 101-114.
53. Demir O, Aysit N, Onder Z, Turkel N, Ozturk G, et al. (2011) ETS-domain transcription factor Elk-1 mediates neuronal survival: SMN as a potential target. Biochim Biophys Acta 1812: 652-662.
54. Hubers L, Valderrama-Carvajal H, Laframboise J, Timbers J, Sanchez G, et al. (2011) HuD interacts with survival motor neuron protein and can rescue spinal muscular atrophy-like neuronal defects. Hum Mol Genet 20: 553-579.
55. Kobayashi DT, Olson RJ, Sly L, Swanson CJ, Chung B, et al. (2011) Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses. PLoS One 6: e24269.
56. Chang HC, Dimlich DN, Yokokura T, Mukherjee A, Kankel MW, et al. (2008) Modeling spinal muscular atrophy in Drosophila. PLoS One 3: e3209.
57. Dimitriadi M, Sleigh JN, Walker A, Chang HC, Sen A, et al. (2010) Conserved genes act as modifiers of invertebrate SMN loss of function defects. PLoS Genet 6: e1001172.
58. Makhortova NR, Hayhurst M, Cerqueira A, Sinor-Anderson AD, Zhao WN, et al. (2011) A screen for regulators of survival of motor neuron protein levels. Nat Chem Biol 7: 544-552.
59. Nolle A, Zeug A, van Bergeijk J, Tonges L, Gerhard R, et al. (2011) The spinal muscular atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin. Hum Mol Genet 20: 4865-4878.
60. Hensel N, Ratzka A, Brinkmann H, Klimaschewski L, Grothe C, et al. (2012) Analysis of the fibroblast growth factor system reveals alterations in a mouse model of spinal muscular atrophy. PLoS One 7: e31202.
61. Locatelli D, Terao M, Fratelli M, Zanetti A, Kurosaki M, et al. (2012) Human Axonal Survival of Motor Neuron (a-SMN) Protein Stimulates Axon Growth, Cell Motility, C-C Motif Ligand 2 (CCL2), and Insulin-like Growth Factor-1 (IGF1) Production. J Biol Chem 287: 25782-25794.
62. Farooq F, Molina FA, Hadwen J, MacKenzie D, Witherspoon L, et al. (2011) Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. J Clin Invest 121: 3042-3050.
63. Bowser R, Lacomis D, (2009) Applying proteomics to the diagnosis and treatment of ALS and related diseases. Muscle Nerve 40: 753-762.
64. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, et al. (2011) Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 69: 655-663.
65. Haslett JN, Sanoudou D, Kho AT, Bennett RR, Greenberg SA, et al. (2002) Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci U S A 99: 15000-15005.
66. Ilzecka J, (2008) Decreased serum endoglin level in patients with amyotrophic lateral sclerosis: a preliminary report. Scand J Clin Lab Invest 68: 348-351.
67. Kolarcik C, Bowser R, (2006) Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease. Mol Diagn Ther 10: 281-292.
68. Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, et al. (2012) Biochemical alterations associated with ALS. Amyotroph Lateral Scler 13: 110-118.
69. Nardo G, Pozzi S, Pignataro M, Lauranzano E, Spano G, et al. (2011) Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One 6: e25545.
70. Ohlendieck K, (2010) Proteomics of skeletal muscle differentiation, neuromuscular disorders and fiber aging. Expert Rev Proteomics 7: 283-296.
71. Pegoraro E, Hoffman EP, Piva L, Gavassini BF, Cagnin S, et al. (2011) SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 76: 219-226.
72. Saris CG, Horvath S, van Vught PW, van Es MA, Blauw HM, et al. (2009) Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients. BMC Genomics 10: 405.
73. Schulte T, Bohringer S, Schols L, Muller T, Fischer C, et al. (2003) Modulation of disease risk according to a cathepsin D/apolipoprotein E genotype in Parkinson's disease. J Neural Transm 110: 749-755.
74. Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, et al. (2009) Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci 1180: 56-67.
75. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, et al. (2012) Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease. Arch Neurol: 1-8.
76. Srivastava T, Darras BT, Wu JS, Rutkove SB, (2012) Machine learning algorithms to classify spinal muscular atrophy subtypes. Neurology 79: 358-364.
77. Heemskerk J, Farkas R, Kaufmann P, (2012) Neuroscience networking: linking discovery to drugs. Neuropsychopharmacology 37: 287-289.